Sofregen Medical Raises $8 Million in Series B Funding Round

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Sofregen Medical, Inc. is an early-stage medical device company, announced today that it has raised $8 million in new funding. The company is developing an advanced platform of products based on silk protein – also known as fibroin – that has been shown to have unique properties for tissue support and regeneration.

The Series B round was led by Anzu Partners from its second venture capital fund focused on breakthrough technologies. The funding will be used to accelerate the development of Sofregen’s unique technology and to support the commercialization and availability of Silk Voice™, a U.S. Food and Drug Administration (FDA)-cleared silk protein treatment for vocal fold medialization and vocal fold insufficiency.

Additionally, the company announced that it has appointed Jonathan T. Hartmann as Chief Executive Officer. Mr. Hartmann was previously CEO of MA-based Axsun Technologies and brings decades of successful leadership experience in the medical technology industry.

“This is an exciting time for Sofregen,” said Hartmann. “We have an outstanding team, strong financial backing, and an incredible platform of clinical and scientific research behind us, and we look forward to making an immediate difference in patient’s lives by launching Silk Voice™ in 2020. We will also be advancing the clinical science to support the use of our unique silk protein materials for medical aesthetics.”

“Sofregen is driving the science behind tissue volume restoration,” said Anh Hoang, Co-founder and Chief Science Officer. “We are harnessing the power of silk protein – a naturally derived, organic, and predictable biomaterial. Our technology enables immediate volume restoration and provides a scaffold that facilitates new tissue generation. This is a valuable feature in facial aesthetic and medical bulking procedures.”

Sofregen also announced that it has appointed Philippe Schaison to its Board of Directors. Dr. Schaison previously served as the CEO, North American of Syneron Candela and President, U.S. Aesthetic & Dermatology at global pharmaceutical company Allergan.

“Sofregen’s technology platform far exceeds anything else in development or on the market today,” said Schaison. “I am excited to be joining the company’s Board of Directors to help it advance a whole range of new products already in development – including the next generation of aesthetic injectables.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.